FLUDEOXYGLUCOSE F 18

N/A

Manufactured by Biomedical Research Foundation of Northwest Louisiana

510 FDA adverse event reports analyzed

Last updated: 2026-04-15

About FLUDEOXYGLUCOSE F 18

FLUDEOXYGLUCOSE F 18 is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Biomedical Research Foundation of Northwest Louisiana. The most commonly reported adverse reactions for FLUDEOXYGLUCOSE F 18 include CYTOKINE RELEASE SYNDROME, DRUG INEFFECTIVE, NAUSEA, OFF LABEL USE, NEUTROPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FLUDEOXYGLUCOSE F 18.

Top Adverse Reactions

CYTOKINE RELEASE SYNDROME23 reports
DRUG INEFFECTIVE16 reports
NAUSEA15 reports
OFF LABEL USE14 reports
NEUTROPENIA13 reports
PLATELET COUNT DECREASED11 reports
PYREXIA11 reports
BONE MARROW FAILURE10 reports
DEATH10 reports
RASH MACULO PAPULAR10 reports
WRONG PRODUCT ADMINISTERED10 reports
COVID 199 reports
DYSPNOEA9 reports
HYPOTENSION9 reports
FEBRILE NEUTROPENIA8 reports
HYPERHIDROSIS8 reports
PRODUCT LABEL ON WRONG PRODUCT8 reports
DIARRHOEA7 reports
MALAISE7 reports
RASH7 reports
VOMITING7 reports
ABDOMINAL DISCOMFORT6 reports
ABDOMINAL PAIN6 reports
ACUTE KIDNEY INJURY6 reports
ANAEMIA6 reports
ASTHENIA6 reports
IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME6 reports
LYMPHOCYTE COUNT ABNORMAL6 reports
PULMONARY MICROEMBOLI6 reports
URTICARIA6 reports
WHITE BLOOD CELL COUNT DECREASED6 reports
ASCITES5 reports
CONFUSIONAL STATE5 reports
EOSINOPHILIA5 reports
FUNGAL SEPSIS5 reports
GENERAL PHYSICAL HEALTH DETERIORATION5 reports
GENERALISED TONIC CLONIC SEIZURE5 reports
PNEUMONIA ASPIRATION5 reports
PRODUCT LABEL ISSUE5 reports
WEIGHT DECREASED5 reports
BODY TEMPERATURE INCREASED4 reports
CYTOMEGALOVIRUS INFECTION REACTIVATION4 reports
DIFFUSE LARGE B CELL LYMPHOMA4 reports
DISEASE PROGRESSION4 reports
ENCEPHALOPATHY4 reports
GASTROINTESTINAL HAEMORRHAGE4 reports
HAEMATOCHEZIA4 reports
LEUKOPENIA4 reports
LOSS OF CONSCIOUSNESS4 reports
MANTLE CELL LYMPHOMA RECURRENT4 reports
MANUFACTURING PROCESS CONTROL PROCEDURE ISSUE4 reports
METASTASES TO LIVER4 reports
NEUTROPHIL COUNT DECREASED4 reports
PANCYTOPENIA4 reports
POSITRON EMISSION TOMOGRAM ABNORMAL4 reports
SECOND PRIMARY MALIGNANCY4 reports
SOMNOLENCE4 reports
THROMBOCYTOPENIA4 reports
URINARY TRACT INFECTION4 reports
ALANINE AMINOTRANSFERASE INCREASED3 reports
ANAPHYLACTIC REACTION3 reports
ASPARTATE AMINOTRANSFERASE INCREASED3 reports
BLOOD BILIRUBIN INCREASED3 reports
CANDIDA INFECTION3 reports
CEREBROVASCULAR ACCIDENT3 reports
CONDITION AGGRAVATED3 reports
CONTRAST MEDIA REACTION3 reports
ERYTHEMA3 reports
FALL3 reports
FEELING HOT3 reports
FLUSHING3 reports
INFECTION3 reports
LUNG DISORDER3 reports
PAIN3 reports
PLEURAL EFFUSION3 reports
PNEUMONITIS3 reports
PRODUCT PREPARATION ERROR3 reports
PRODUCT STERILITY ISSUE3 reports
PRURITUS3 reports
RASH ERYTHEMATOUS3 reports
SEPSIS3 reports
TREMOR3 reports
UNRESPONSIVE TO STIMULI3 reports
WHEEZING3 reports
ACUTE RESPIRATORY FAILURE2 reports
AGITATION2 reports
ANXIETY2 reports
APHASIA2 reports
BLOOD GLUCOSE DECREASED2 reports
BRADYCARDIA2 reports
BREAST CANCER2 reports
CHILLS2 reports
CHRONIC KIDNEY DISEASE2 reports
CHRONIC OBSTRUCTIVE PULMONARY DISEASE2 reports
COLD SWEAT2 reports
CONSTIPATION2 reports
COUGH2 reports
COVID 19 PNEUMONIA2 reports
DEVICE RELATED BACTERAEMIA2 reports
DIZZINESS2 reports

Report Outcomes

Out of 257 classified reports for FLUDEOXYGLUCOSE F 18:

Serious 77.0%Non-Serious 23.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male126 (53.8%)
Female103 (44.0%)
Unknown5 (2.1%)

Reports by Age

Age 7512 reports
Age 6010 reports
Age 6310 reports
Age 719 reports
Age 618 reports
Age 687 reports
Age 566 reports
Age 576 reports
Age 596 reports
Age 736 reports
Age 746 reports
Age 515 reports
Age 525 reports
Age 645 reports
Age 665 reports
Age 705 reports
Age 785 reports
Age 805 reports
Age 444 reports
Age 534 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with FLUDEOXYGLUCOSE F 18?

This profile reflects 510 FDA FAERS reports that mention FLUDEOXYGLUCOSE F 18. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for FLUDEOXYGLUCOSE F 18?

Frequently reported terms in FAERS include CYTOKINE RELEASE SYNDROME, DRUG INEFFECTIVE, NAUSEA, OFF LABEL USE, NEUTROPENIA, PLATELET COUNT DECREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures FLUDEOXYGLUCOSE F 18?

Labeling and FAERS entries often list Biomedical Research Foundation of Northwest Louisiana in connection with FLUDEOXYGLUCOSE F 18. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.